Inflammation and type 2 diabetes

Diabetes and Metabolism

Volumn 38, Issue 3, 2012, Pages 183-191

  Calle, M C ^a   Fernandez, M L ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Adiponectin; C reactive protein; Cardiovascular diseases; Diet; The metabolic syndrome; TNF ; Type 2 diabetes; Weight loss

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; FATTY ACID; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PATTERN RECOGNITION RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN IRE1; REACTIVE OXYGEN METABOLITE; RESISTIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; ATHEROSCLEROSIS; BODY MASS; CATABOLISM; CELL ADHESION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL STRESS; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENDOPLASMIC RETICULUM; FATTY ACID OXIDATION; FIBRINOGEN BLOOD LEVEL; GLUCOSE METABOLISM; GLYCATION; HALF LIFE TIME; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; LIPOLYSIS; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNFOLDED PROTEIN RESPONSE;

ADIPONECTIN; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863455384     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2011.11.006     Document Type: Review

References (93)

1. Ross R. Atherosclerosis -an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Puglisi M., Fernandez M.L. Modulation of C-reactive protein, tumor necrosis-alpha and adiponectin by diet, exercise and weight loss. J Nutr 2008, 138:2293-2296.
3. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003, 285:E527-E533.
4. Petersen A.M.W., Pedersen B.K. The anti-inflammatory effect of exercise. J Applied Physiol 2005, 98:1154-1162.
5. Murphy K., Travers P., Walport M. Janeway's immunobiology 2008, Garland Science, New York. 7th ed.
6. Ekmekci H., Ekmekci O.B. The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thromb Hemost 2006, 12:163-168.
7. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., Yoshida M., Ding H.A., Gimbrone Ma, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999, 398:718-723.
8. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119.
9. Dos Santos M.G., Pegoraro M., Sandrini F., Macuco E.C. Risk factors for the development of atherosclerosis in childhood and adolescence. Arq Bras Cardiol 2008, 90:276-283.
10. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
11. Cawthorn W.P., Sethi J.K. TNF-α and adipocyte biology. FEBS Lett 2008, 582:117-131.
12. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
13. Ungvari Z., Sonntag W.E., Csiszar A. Mitochondria and aging in the vascular system. J Mol Med 2010, 88:1021-1027.
14. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-907.
15. Chung H.Y., Cesari M., Anton S., Marsetti E., Giovannini S., Seo A.Y., et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev 2009, 8:18-30.
16. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008, 8:923-934.
17. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Brit J Nutr 2004, 92:347-355.
18. Rupnick M.A., Panigrahy D., Zhang C.Y., Dallabrida S.M., Lowell B.B., Langer R., et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci 2002, 99:10730-10735.
19. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
20. Rader D.J., Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008, 451:904-913.
21. Wang B., Wood I.S., Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. J Endocrinol 2008, 198:127-134.
22. Wood I.S., De Heredia F.P., Wang B., Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 2009, 68:370-377.
23. Peppa M., Stavroulakis P., Raptis S.A. Advanced glycoxidation products and impaired diabetic wound healing. Wound Repair Regen 2009, 17:461-472.
24. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circulation Res 2010, 107:1058-1070.
25. Yamagishi S., Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite edition) 2010, 2:1184-1195.
26. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., Dardaine V., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002, 99:15596-15601.
27. Devaraj S., Singh U., Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009, 55:229-238.
28. Alexandraki K., Piperi C., Kalofoutis C., Singh J., Alaveras A., Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Ann NY Acad Sci 2006, 1084:89-117.
29. Pasceri V., Willerson J.T., Yeh E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
30. Pasceri V., Chang J., Willerson J.T., Yeh E.T.H. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103:2531-2534.
31. Pannacciulli N., Cantatore F.P., Minenna A., Bellacicco M., Giorgino R., De, et al. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obesity 2001, 25:1416-1420.
32. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis. From pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
33. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelain J.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008, 359:2195-2207.
34. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. Moving an inflammatory hypothesis toward consensus. J Am Coll Card 2007, 49:2129-2138.
35. De Ferranti S., Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin. Chim Acta 2002, 317:1-15.
36. Ouchi N., Kihara S., Funahashi T., Nakamura T., Nishida M., Kumada M., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
37. Panagiotakos D.B., Pitsavos C., Chrysohoou C., Skoumas E., Stefanadis C. Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study. Vasc Med 2008, 13:113-121.
38. Chen K., Li F., Li J., Cai H., Strom S., Bisello A., et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006, 12:425-432.
39. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., Nordestgarrd B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 1897-1908.
40. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
41. Stephens J.M., Lee J., Pilch P.F. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997, 272:971-976.
42. Wang B., Trayhurn P. Acute and prolonged effects of TNF-α on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006, 452:418-427.
43. Jovinge S., Hamsten A., Torvall P., Proudler A., Bavenholm P., Ericsson C.G., et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998, 47:113-118.
44. Celec P. Nuclear factor kappa B-molecular medicine. Biomed Pharmacothe 2004, 58:365-371.
45. Murray D.R., Freeman G.L. Proinflammatory cytokines. Predictors of a failing heart?. Circulation 2003, 107:1460-1462.
46. Qin B., Anderson R.A., Adeli K. Tumor necrosis factor-α directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am J Physiol Gastrointes Liver Physiol 2008, 294:G1120-G1129.
47. Bastard J.P., Jardel C., Bruckert E., Vidal H., Hainque B. Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity. Diabetes Obes Metab 2000, 2:323-325.
48. Sharman M.J., Volek J.S. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci (Lond) 2004, 107:365-369.
49. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
50. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
51. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
52. Coughlin C.C., Finck B.N., Eagon J.C., Halpin V.J., Magkos F., Mohammed B.S., et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity 2007, 15:640-645.
53. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
54. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
55. Cnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46:459-469.
56. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001, 7:941-946.
57. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
58. Julius U. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 2003, 111:246-250.
59. Viollet B., Foretz M., Guigas B., Horman S., Dentin R., Bertrand L., et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006, 574:41-53.
60. Madsen E.L., Rissanen A., Bruun J.M., Skogstrand K., Tonstad S., Hougaard D.M., et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008, 158:179-187.
61. Ng T.W., Watts G., Barrett P.H., Rye K.A., Chan D.C. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 2007, 30:2945-2950.
62. Simpson K.A., Singh M.A. Effects of exercise on adiponectin: a systematic review. Obesity (Silver Spring) 2008, 16:241-256.
63. Egger G., Dixon J. Should obesity be the main game? Or do we need an environmental makeover to combat the inflammatory and chronic disease epidemics? Viewpoint. Obesity Rev 2009, 10:237-249.
64. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115:1111-1119.
65. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
66. Fasshauer M., Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003, 46:1594-1603.
67. Hotamisligil G.S. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int J Obes (London) 2008, 32:S52-S54.
68. Rønn S.G., Billestrup N., Mandrup-Poulsen T. Diabetes and suppressors of cytokine signaling proteins. Diabetes 2007, 56:541-548.
69. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003, 301:1045-1050.
70. Yuan G., Chen X., Ma Q., Qiao J., Li R., Li X., et al. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 2007, 194:275-281.
71. Coppack S.W., Evans R.D., Fisher R.M., Frayn K.N., Gibbons G.F., et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metab Clin Exp 1992, 41:264-272.
72. Kim J.A., Montagnani M., Kwang K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
73. Cersosimo E., DeFronzo R.A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006, 22:423-436.
74. Rucelin R., Serino M., Chabo C., Blasco-Baque V., Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetologia 2011, 48:257-263.
75. Knights D., Costello E., Knight R. Supervised classification of human microbiota. FEMS Microbiol Rev 2010, 35:343-359.
76. Zoetandal E.G., Akkermans A.D., De Vos W.M. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998, 64:3854-3859.
77. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
78. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
79. Larsen N., Vogensen F.K., van den Berg F.W., Nielsen D.S., Andreasen A.S., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLos One 2010, 5:e9085.
80. Amar J., Serino M., Lange C., Cahbo C., Iacovoni J., Mondot S., et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia 2011, 54:3055-3061.
81. Amar J., Chabo C., Waget A., Klopp P., Vachoux C. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011, 3:559-572.
82. Wannamethee S.G., Whincup P.H., Thomas M.C., Sattar N. Associations between dietary fiber and inflammation, hepatic function, and risk of type 2 diabetes in older men: potential mechanisms for the benefits of fiber on diabetes risk. Diabetes Care 2009, 32:1823-1825.
83. Masters R.C., Liese A.D., Haffner S.M., Wagenknecht L.E., Hanley A.J. Whole and refined grain intakes are related to inflammatory protein concentrations in human plasma. J Nutr 2010, 140:587-594.
84. Kant A.K. Dietary patterns: Biomarkers and chronic disease risk. Appl Physiol Nutr Metab 2010, 35:199-206.
85. Nettleton J.A., Steffen L.M., Mayer-Davis E.J., Jenny N.S., et al. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2006, 83:1369-1379.
86. Lopez-Garcia E., Schulze M.B., Fung T.T., Meigs J.B., Rifai N., Manson J.E., et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2004, 80:1029-1035.
87. Heidemann C., Hoffmann K., Spranger J., Klipstein-Grobusch K., Möhlig M., Pfeiffer A.F., et al. A dietary pattern protective against type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC) - Potsdam Study cohort. Diabetologia 2005, 48:1126-1134.
88. Esmaillzadeh A., Kimiagar M., Mehrabi Y., Azadbakht L., Hu F.B., Willett W.C. Dietary patterns and markers of systemic inflammation among Iranian women. J Nutr 2007, 137:992-998.
89. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292:1440-1446.
90. Giugliano D., Ceriello A., Esposito K. The effects of diet on inflammation. Emphasis on the metabolic syndrome. J Am Coll Cardiol 2006, 48:677-685.
91. Herder C., Peltonen M., Koenig W., Sütfels K., Lindström J., Martin S., et al. Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia 2009, 52:433-442.
92. Zern T.L., Wood R., Greene C.M., West K.L., Liu Y., Aggarwal D., et al. Grape polyphenols lower plasma lipids and apolipoproteins associated with increased risk for cardiovascular disease in pre and post-menopausal women. J Nutr 2005, 135:1911-1947.
93. Puglisi M., Vaishnav U., Shrestha S., Torres-Gonzalez M., Wood R.J., Volek J.S., et al. Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines. Lipids Health Dis 2008, 7:14.